Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRLM.L Regulatory News (RLM)

  • There is currently no data for RLM

Board Changes

19 Jun 2015 07:00

RNS Number : 6253Q
PuriCore Plc
19 June 2015
 



PuriCore plc

("PuriCore" or the "Company")

 

Board Changes

 

Michael Ashton retires as CEO and Executive Director

 

Alex Martin assumes role as CEO and Executive Director

 

19 June 2015 - PuriCore plc (AIM: PURI), an international company focused on safe and effective protection against the spread of infectious pathogens, today announces that following the Company's Annual General Meeting yesterday, Michael Ashton has retired as Chief Executive Officer (CEO) and Executive Director, in line with the Company's announcement in October 2014. As previously announced, Alex Martin assumes the role of CEO and joins the Board of Directors with immediate effect.

 

Charles Spicer, Non-Executive Chairman of PuriCore, commented:

"We are very grateful to Michael for his significant contributions over the last three years, having stepped in to lead the Company at a challenging time in its evolution and implementing strategic changes, which have set the Company on a positive footing for the future. On behalf of the Board and Company employees, we thank Michael for his leadership in guiding the business to where it is today and we wish him all the best."

 

 

-Ends-

 

 

Enquiries:

 

PuriCore plc

+44 (0) 20 3727 1000

Charles Spicer, Non-Executive Chairman

FTI Consulting

+44 (0) 20 3727 1000

Simon Conway / Mo Noonan / Victoria Foster Mitchell

N+1 Singer (Nominated Adviser & Broker)

+44 (0) 20 7496 3000

Aubrey Powell / Jen Boorer / Thomas Smale

 

 

About PuriCore

PuriCore is an international company focused on developing and commercialising safe and effective products to protect against the spread of infectious pathogens based on its proprietary hypochlorous acid platform technology. Its products are currently used in two broad market segments: Supermarket Retail and Health Sciences. PuriCore's products do not cause harm to human or animal life or to the environment.

 

In the Supermarket Retail segment, PuriCore offers products to US retailers for use in their fresh produce departments to improve food safety and quality, to extend shelf life and to decrease food wastage. Our product is an eco-friendly, food-safe sanitising solution at a neutral PH that is used to protect produce from cross contamination and improve freshness. Our Sterilox Fresh Systems are capital equipment that are installed at customer locations and allow for generation of solution as needed at the store. ProduceFresh is our concentrate bottled version providing the same levels of stability, freshness and quality in a convenient consumable package. Additionally, the Company's FloraFresh® products, also sold as a concentrate in bottled form, protect against fungal growth and extend the life of cut flowers, with an initial focus on supermarket floral departments.

 

In Health Sciences, PuriCore's Wound Care business provides products that are used to treat chronic and acute wounds, including diabetic ulcers and burns in humans. A range of products have also been developed to manage wounds in companion and farm animals. The Company's Dermatology business is currently focused on treatments for atopic dermatitis. PuriCore is headquartered in Malvern, Pennsylvania.

 

 

Certain statements made in this announcement are forward-looking statements. These forward-looking statements are not historical facts but rather are based on the Company's current expectations, estimates, and projections about its industry; its beliefs; and assumptions. Words such as 'anticipates,' 'expects,' 'intends,' 'plans,' 'believes,' 'seeks,' 'estimates,' and similar expressions are intended to identify forward-looking statements. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond the Company's control, are difficult to predict, and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. The Company cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of the Company only as of the date of this announcement. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. The Company will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances, or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BOAVVLFFEQFBBBL
Date   Source Headline
5th Sep 20114:35 pmRNSPrice Monitoring Extension
23rd Aug 20117:00 amRNSHalf Yearly Report
21st Jul 20117:00 amRNSRe Settlement with Misonix
15th Jun 201110:06 amRNSResult of AGM
18th May 20117:00 amRNSAnnual Information Update
17th May 20114:58 pmRNSUK Division Update
6th May 20117:00 amRNSAnnual Report and Accounts Available
28th Apr 20116:21 pmRNSFinal Results
28th Apr 20116:21 pmRNSInterim Management Statement
4th Apr 20112:29 pmRNSHolding(s) in Company
31st Mar 20114:53 pmRNSHolding(s) in Company
31st Mar 20114:52 pmRNSHolding(s) in Company
31st Mar 20114:51 pmRNSHolding(s) in Company
31st Mar 20117:00 amRNSTotal Voting Rights
22nd Mar 20117:00 amRNSPlacing of New Ordinary Shares
15th Mar 20114:24 pmRNSPotential Sale of Endoscopy Division
4th Feb 201111:51 amRNSBlocklisting Interim Review
2nd Feb 20111:18 pmRNSPre-Close Trading Update
9th Dec 20108:58 amRNSBlocklisting Interim Review
30th Nov 20107:00 amRNSChange of Adviser
8th Nov 20107:00 amRNSInterim Management Statement
29th Oct 20109:56 amRNSResult of General Meeting
11th Oct 20104:00 pmRNSProposed New Long Term Incentive Plan
2nd Sep 20102:44 pmRNSDirector/PDMR Shareholding
31st Aug 20107:00 amRNSHalf Yearly Report
9th Aug 20107:00 amRNSTrading Statement
22nd Jul 20101:36 pmRNSHolding(s) in Company
22nd Jul 20101:30 pmRNSHolding(s) in Company
30th Jun 20109:47 amRNSResult of AGM
21st Jun 20101:10 pmRNSReplacement: Director/PDMR Shareholding
21st Jun 20107:00 amRNSDirector/PDMR Shareholding
16th Jun 20107:00 amRNSBoard Change
14th Jun 20101:38 pmRNS2010 General Meeting Results
14th Jun 20109:16 amRNSAnnual Information Update
28th May 20102:55 pmRNSPublication of Circular
28th May 20107:32 amRNSResumption of Trading
28th May 20107:30 amRNSRestoration
28th May 20107:02 amRNSInterim Management Statement
28th May 20107:01 amRNSFinal Results
28th May 20107:00 amRNSIssue of Secured Convertible Loan Notes
24th May 20102:55 pmRNSHolding(s) in Company
30th Apr 20107:54 amRNSTemporary Suspension
30th Apr 20107:30 amRNSTemporary Suspension - PuriCore Plc
23rd Apr 20107:00 amRNSPuriCore Raises $1.8 Million
24th Feb 20107:00 amRNSBlocklisting Interim Review
20th Jan 20107:00 amRNSTrading Statement
4th Dec 20097:00 amRNSWins Emerging Life Sciences Company of the Year
12th Nov 20097:00 amRNSChange of Adviser
11th Nov 20092:00 pmRNSClinical Results for Vashe Wound Therapy
3rd Nov 20097:00 amRNSInterim Management Statement

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.